138 related articles for article (PubMed ID: 38636269)
1. Rituximab-induced gut microbiota changes in Chinese neuromyelitis optica spectrum disorders.
Chen H; Xu Z; Zhou Y; Jiang YH; Chen J; Xiong Y; Zhou M; Wu X; Hong D
Mult Scler Relat Disord; 2024 Jun; 86():105606. PubMed ID: 38636269
[TBL] [Abstract][Full Text] [Related]
2. Lack of short-chain fatty acids and overgrowth of opportunistic pathogens define dysbiosis of neuromyelitis optica spectrum disorders: A Chinese pilot study.
Gong J; Qiu W; Zeng Q; Liu X; Sun X; Li H; Yang Y; Wu A; Bao J; Wang Y; Shu Y; Hu X; Bellanti JA; Zheng SG; Lu Y; Lu Z
Mult Scler; 2019 Aug; 25(9):1316-1325. PubMed ID: 30113252
[TBL] [Abstract][Full Text] [Related]
3. Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study.
Shi Z; Qiu Y; Wang J; Fang Y; Zhang Y; Chen H; Du Q; Zhao Z; Yan C; Yang M; Zhou H
J Neuroimmunol; 2020 Feb; 339():577126. PubMed ID: 31841737
[TBL] [Abstract][Full Text] [Related]
4. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
[TBL] [Abstract][Full Text] [Related]
5. Intestinal Barrier Breakdown and Mucosal Microbiota Disturbance in Neuromyelitis Optical Spectrum Disorders.
Cui C; Tan S; Tao L; Gong J; Chang Y; Wang Y; Fan P; He D; Ruan Y; Qiu W
Front Immunol; 2020; 11():2101. PubMed ID: 32983166
[TBL] [Abstract][Full Text] [Related]
6. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
7. Characteristic of gut microbiota in southeastern Chinese patients with neuromyelitis optica spectrum disorders.
Zhang J; Xu YF; Wu L; Li HF; Wu ZY
Mult Scler Relat Disord; 2020 Sep; 44():102217. PubMed ID: 32534438
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Ma J; Yu H; Wang H; Zhang X; Feng K
J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
[TBL] [Abstract][Full Text] [Related]
10. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
Shaygannejad V; Fayyazi E; Badihian S; Mirmosayyeb O; Manouchehri N; Ashtari F; Asgari N
J Neurol; 2019 Mar; 266(3):642-650. PubMed ID: 30635724
[TBL] [Abstract][Full Text] [Related]
11. Potential role of the gut microbiota in neuromyelitis optica spectrum disorder: Implication for intervention.
Cui C; Ruan Y; Qiu W
J Clin Neurosci; 2020 Dec; 82(Pt B):193-199. PubMed ID: 33257156
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
[TBL] [Abstract][Full Text] [Related]
13. Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder.
Lin J; Li X; Xue B; Tong Q; Chen Z; Zhu W; Li J; Xia J
J Neuroimmunol; 2018 Apr; 317():1-4. PubMed ID: 29501080
[TBL] [Abstract][Full Text] [Related]
14. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H; Bernard-Valnet R; Lebrun C; Outteryck O; Audoin B; Bourre B; Pittion S; Wiertlewski S; Ouallet JC; Neau JP; Ciron J; Clavelou P; Marignier R; Brassat D
J Neurol; 2015 Oct; 262(10):2329-35. PubMed ID: 26194198
[TBL] [Abstract][Full Text] [Related]
15. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
17. Gut Microbiome and Bile Acid Metabolism Induced the Activation of CXCR5+ CD4+ T Follicular Helper Cells to Participate in Neuromyelitis Optica Spectrum Disorder Recurrence.
Cheng X; Zhou L; Li Z; Shen S; Zhao Y; Liu C; Zhong X; Chang Y; Kermode AG; Qiu W
Front Immunol; 2022; 13():827865. PubMed ID: 35126400
[TBL] [Abstract][Full Text] [Related]
18. Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
Gomez-Figueroa E; Noriega-Morales G; Casallas-Vanegas A; Zabala-Angeles I; Garcia-Estrada C; Neri D; Sarachaga AJ; Rivas-Alonso V; Corona-Vazquez T; Flores-Rivera J
Clin Neurol Neurosurg; 2020 Sep; 196():106007. PubMed ID: 32559706
[TBL] [Abstract][Full Text] [Related]
19. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
20. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
